🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Thrilled to be in our new digs! x.com/meetclora/stat…

Companies who use Clora to hire life science consultants save 70% of costs compared to those who use traditional recruiting methods. Learn more - hubs.ly/H0dd-Jv0 #lifescience #pharma #biotech #biopharma #recruiting #consulting

Come join us at Clora if you’re passionate about biopharma and tech.

Because hiring life science consultants is faster and easier than ever, companies will be able to piece together the perfect team of experts with extreme agility. Here's how to assemble yours - hubs.ly/H0dnvZj0

We are excited to announce the launch of The Clora Blog, a resource dedicated to sharing insights on how to consult, build, and lead teams in the life science industry! Subscribe for new posts every week - hubs.ly/H0dnwjQ0

We created Clora after spending years being frustrated with the processes of hiring flexible life science experts. Learn more about our mission - hubs.ly/H0dnwpM0 #pharma #biopharma #biotech #lifesciences

Excited to share the recent interview our CEO Rahul Chaturvedi and Alok Tayi VP of Life Sciences at Egnyte had with Stephan Kontos, Co-Founder and CSO at Anokion! #biotech #pharma #autoimmune #celiac bit.ly/2LsgdMt

Court rulings dismissed recent challenges by Bristol Myers Squibb & Johnson & Johnson against the US Inflation Reduction Act's pricing rules. This marks a defining moment for the future of drug development and healthcare advancements. ow.ly/gAWR50RIMEn

Heading to #BIO2024 in San Diego in a few weeks! Excited to meet with industry leaders and discuss how @meetclora is solving some of the biggest challenges teams face today. Send me a message if you want to meet up!

Biotech faced big layoffs in Q1 of this year, with 57 companies affected, matching Q1 2023 but up 90% from 2022: ow.ly/WCeJ50RT3ac How are you navigating the current environment? What does the future of work in #biotech look like? Comment or message me.

Excited to share the latest Emmanuele episode with Robert Ang, CEO of Vor Bio. We discussed his journey from #medicine to #VC to #entrepreneurship, next-gen #cancer therapies, and his approach to indication selection. Huge thanks to Robert for his insights!

I will be at #BIO2024 next week discussing industry innovations for Biotech2050 Podcast and sharing how @meetclora is derisking #drugdevelopment by modernizing operating models and #hiring. If you'll be attending, let's meet! Send me a message to schedule time to connect.

It was great catching up with @Ptipirneni of MorphicTx on the new episode of Biotech2050 Podcast. Learn about his journey to being a first-time CEO, integrin #biology, the role of BD in #biopharma, and key drivers leading to the growing potential in the #autoimmune space.

Excited to have Ken Keller, President & CEO of Daiichi Sankyo US, on #Biotech2050 with Rahul Chaturvedi! 🎙️ We discuss the future of cancer therapies, innovative ADCs, and insights into partnerships and team building. Listen to the episode: on.soundcloud.com/zGKkxeZehvXBZ7… #Biotech #CancerResearch

Had a great conversation with Dave Bearss, CEO of Halia Therapeutics, about the founding of the company, how their initial focus on the APOE4 gene led them to focus on inflammation, and their non-traditional financing strategy for clinical stage assets. Tune in.

I spoke with Abe Ceesay, CEO of Rapport Therapeutics, on what it takes to scale talent, lead with a servant mindset, and drive smart risk-taking in biotech. Hear his take on building emotional safety and more.

Join me on the Biotech2050 Podcast podcast with Bharatt Chowrira & Eric Elenko of PureTech. We dive into their model for tackling big problems, the founding of KARUNA THERAPEUTICS, and the benefits of evergreen funding.

Join me on the Biotech2050 Podcast podcast with Kristin Yarema, President & CEO of Poseida Therapeutics. We discuss corporate culture, Allogeneic CAR-T therapies, and bridging the gap between physicians’ visions for medicine and investor priorities.

Uncertainty is the new normal in biotech and pharma. At @meetclora, we explore how leaders are shifting to flexible, dynamic talent strategies to stay resilient in a volatile world. Read our latest report on adapting to change: linkedin.com/pulse/meeting-…

To tame Type 2 diabetes, feed your inner beasts. Literally. buff.ly/2Fv54Gc